According to TipRanks, Mamtani is an analyst with an average return of -30.0% and a 21.94% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Agenus.
Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $28.83, implying a 167.19% upside from current levels. In a report released today, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $20.00 price target.
The company has a one-year high of $23.49 and a one-year low of $3.83. Currently, Altimmune has an average volume of 2.33M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
Read More on ALT: